Serial biopsy of pancreatic ductal adenocarcinoma (pDAc), to chart tumour evolution presents a significant challenge. We examined the utility of circulating free DNA (cfDNA) as a minimally invasive approach across a cohort of 55 treatment-naïve patients with PDAC; 31 with metastatic and 24 with locally advanced disease. Somatic mutations in cfDNA were detected using next generation sequencing in 15/24 (62.5%) and 27/31 (87%) of patients with locally advanced and metastatic disease, respectively. Copy number changes were detected in cfDNA of 10 patients of whom 7 exhibited gain of chromosome 12p harbouring KRAS as well as a canonical KRAS codon 12 mutation. In multivariable Cox Regression analysis, we show for the first time that patients with KRAS copy number gain and KRAS mutation have significantly worse outcomes, suggesting that this may be linked to PDAC progression. The simple cfDnA assay we describe will enable determination of the presence of KRAS copy number gain and KRAS mutations in larger studies and clinical trials.
No somatic mutations or copy number alterations were detected in 16 non-cancer controls ( Table 1 ). No significant differences were observed in yield of cfDNA detected between the 31 patients with metastatic and 24 with locally advanced PDAC (p-value = 0.19; Fig. 2 ). From cfDNA NGS, both CNA and somatic mutations were elevated in the patients with metastatic disease compared to the patients with locally advanced disease (p-values of 0.0164 and 0.0049, respectively, Fig. 2B,C) . Somatic mutations were detected in 87% (27/31) and 54% (13/24) of the samples from patients with metastatic and locally advanced disease, respectively. Known non-synonymous activating KRAS mutations, confirmed by ddPCR, were detected in 35% (11/31) and 12.5% (3/24) of samples from patients with metastatic and locally advanced disease respectively. In addition to the 14 mutations detected by NGS, a further seven KRAS mutations (four metastatic, three locally advanced) were detected using ddPCR, which were below the 2.5% VAF (Variant Allele frequency) threshold used for NGS analysis (Fig. 1B ). In keeping with previous studies, NGS of cfDNA from the patiens with metastatic disease also identified canonical TP53 and KMT2D mutations at frequencies of 29% (9/31) and 16% (5/31) respectively 6 ( Fig. 1B) .
Measurable copy number alterations (CNA) were detected in 10 of the 55 patients' cfDNA samples (nine metastatic, one locally advanced), of whom seven exhibited a gain in chromosome 12p that harbours KRAS (Fig. 1B) . All seven PDAC cfDNA samples with copy number gain (CNG) of KRAS also exhibited non-synonymous somatic mutations in KRAS ( Fig. 1B and Supplementary Table 1 ).
Kaplan-Meier analysis of overall survival (OS) based on KRAS mutation alone (7/55), KRAS mutation and CNG (7/55) and with KRAS wild-type (34/55), revealed best prognosis for patients with KRAS wild-type (median survival 10.6 months), followed by patients with KRAS mutation without CNG (median survival 5.5 months). The worst prognosis was associated with the combination of a KRAS mutation and CNG (median survival 2. 5   RUNX1T1  SMARCA4  TMPRSS2  PCDHGA5  PDCD1LG2   KRAS  TP53  TTN  KMT2D  KDM5A  ABI1  MYC  PAX2  PIK3C2B  PTPRC  FGFR4  HOXA11  NUP214  PDE4DIP   PMS2  RECQL4  RIMS2  SLC45A3  SMAD4  TCF4  TET1  WT1  SEPT6  ACSL6  AFF1  AFF4  ARID1A   ATM  ATR  BCL6  BCL9  CBL  CDKN2A  CLTCL1  EPHA10  EPHA5  ERBB4  ERCC3  EZH2  FANCA  GPC3  IDH1 Combined mutational and copy number plot for the 85 genes that were positive for at least 1 mutation across all 55 cfDNA samples analysed. Boxes coloured orange represent mutation and a copy number gain (CNG), yellow mutation and copy number loss (CNL), green mutation, red CNG, and blue for CNL. (C) Kaplan-Meier analysis of the overall survival according to KRAS mutation alone (7/55), KRAS mutation and copy number gain (7/55), along with KRAS wild-type (41/55) in 55 patients revealed best prognosis for patients with KRAS wild-type, with a median survival of 10.6 months, followed by patients with KRAS mutation alone with a median survival of 5.6 months. Patients with both the KRAS mutation and copy number gain had the worst prognosis with a median survival of 2.5 months (overall Log-rank test p-value = < 0.0001). KRAS WT vs KRAS MUT only Log-rank p-value = 0.0610, KRAS WT vs KRAS CN gain + MUT Log-rank p = value = 0.0012 and KRAS MUT only vs KRAS CN gain + MUT Log-rank p-value = < 0.0001. (D) Hazard ratios for the factors that were used in a multivariable analysis.
Discussion
In this pilot study of 55 patients with PDAC, we applied NGS and ddPCR to cfDNA to establish which readouts, if any, are linked to clinical outcomes. Although we see a relatively short median survival of 7.99 months compared to the 19.77 months reported in a TCGA study 7 , this most likely reflects differences in staging with the TCGA cohort comprising operable localised disease whereas our cohort includes patients with locally advanced and metastatic disease, resulting in a shorter median survival, in line with those reported by other groups 8, 9 . Analysis of cfDNA from each patient revealed the presence of a canonical KRAS somatic mutation, which was determined by ddPCR and was found to be 38% (21/55) overall; 48% (15/31) in metastatic disease and 25% (6/24) in locally advanced disease, in keeping with other published studies 6 . Although our detection rate of 38% for the presence of a KRAS mutation in patient cfDNA is in line with other reports, there is considerable variation in reported frequencies (27~93%) 10, 11 which may reflect the methodologies employed, as well as the variability of KRAS allelic ratios in the tumour 10 and the low ctDNA burden associated with pancreatic cancer 12 . Analysis of a larger cohort with a consistent specified cfDNA methodology is required to assess the affect of KRAS variation on the accuracy of prognosis. As expected, from the threshold of detection used for the targeted NGS in this study (2.5%) 13 , only 14/21 ddPCR positive samples were found to harbour targeted NGS somatic KRAS mutations ( Supplementary Table 1 ). However, by extending the NGS analysis to an additional 640 genes, somatic mutations were detected in 71% (39/55) in all samples; 84% (26/31) in metastatic disease and 50% (12/24) in locally advanced disease. The most striking novel observation that emerged from this study was that >10% of patients with PDAC harboured both a KRAS mutation and a KRAS CNG, and that the latter correlated with a worsened prognosis. Although amplified mutated KRAS has been reported in non-small cell lung cancer (NSCLC) and is also associated with poor clinical outcome 14 , this is the first report in PDAC. In addition to identifying CNG of KRAS, we also noted four cases where TP53 mutations were accompanied by copy number loss (CNL), suggesting that further analysis of a larger patient group may also identify CNL as a prognostic biomarker. www.nature.com/scientificreports www.nature.com/scientificreports/ We now have the opportunity to verify these initial results by examining additional patient cfDNAs from the on-going Precision-Panc clinical trial, and serial measurements may inform response to treatment 15 .
Our results demonstrate cfDNA analysis can be used in advanced disease to identify patients with worse prognosis who may benefit from more aggressive chemotherapy. In addition, the identification of KRAS CNG and mutation as a poor prognostic factor, could also help to identify patients with resectable disease with higher risk of early tumour relapse, who may benefit from additional staging imaging before surgery (i.e. Magnetic resonance imaging of the liver or 18 fluorodeoxyglucose (FDG)-positron emission tomograph) or potential neo-adjuvant. circulating cell free DnA preparation. Plasma and cfDNA were isolated as previously described 16 .
Materials and Methods
Germline DNA was isolated from EDTA whole blood, using QIAmp Blood Mini Kit (Qiagen, Hilden, Germany) as per manufacturer's instructions. nGS library preparation and sequencing. Whole genome sequencing (WGS) of cfDNA and corresponding germline DNA from the patients as well as non-cancer controls were carried out using the Accel-NGS ® 2 S Plus DNA Library Kit as previously described 16 . targeted nGS analysis. Targeted NGS of 641 cancer-associated genes was carried out using Agilent SureSelectXT as described previously 13 . Somatic mutation detection from targeted re-sequencing data. Three mutation callers were used: 
